EUVIMEDEUVIMED entdecken
Open Access

Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients

D A Trukhina, E G Przhiyalkovskaya, Zh E Belaya, A Yu Grigoriev, V N Azizyan, E O Mamedova, L Ya Rozhinskaya, A M Lapshina, E A Pigarova, L K Dzeranova, N M Platonova, E A Troshina und 1 weitere

Problems of Endocrinology · 2023

DOI: 10.14341/probl13325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Problems of Endocrinology, 2023. Verfasst von D A Trukhina und 12 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Research Centre. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Thyrotropin, Adenoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND : Thyrotropin-secreting pituitary adenomas (TSH-PA) are a rare cause of thyrotoxicosis and account for 0.5-2% of all pituitary adenomas. Taking into account the rarity of the disease, it is extremely important to analyze each case of TSH-PA. AIM: To analyze the clinical characteristics and treatment outcomes of patients with TSH-PA, as well as to determine preoperative and early postoperative factors that predict long-term remission. MATERIALS AND METHODS : In a single-center retrospective study we analyzed clinical signs, laboratory and instrumental studies, as well as the treatment outcomes of patients with TSH-PA from 2010 to 2023. Preoperative factors, as well as TSH level measured on day 3 postoperatively, were evaluated for their ability to predict long-term remission when comparing groups of patients with and without remission. RESULTS: The study included 45 patients with TSH-PA (14 men, 31 women), with a median age of 45 years [30; 57]. The most common clinical manifestations of TSH-PA were: cardiac arrhythmia in 37 (82.2%) patients, thyroid pathology in 27 (60%), neurological disorders in 24 (53.35%). Most PAs were macroadenomas (n=35, 77.8%). Preoperatively, 28 (77.8%) patients received somatostatin analogs, and 20 (71.4%) patients were euthyroid at the time of surgery. Surgical treatment was performed in 36 (80%) patients, postoperative remission was achieved in 31 cases (86.1%). Administration of somatostatin analogues to patients with no remission/relapse after surgery lead to the remission in 100% of cases (4/4). A 1 mm increase in PA size raised the odds of recurrence/no remission by 1.15-fold,and PA invasion during surgery — by 5.129 fold. A TSH level on day 3 postoperatively above 0.391 mIU/L (AUC, 0.952; 95% CI 0.873–1.000; standard error 0.04; p0.391 mU/l) to predict recurrence of TSH-PA, which requires validation on an expanded number of cases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pituitary NeoplasmsThyrotropinAdenomaHumansMaleFemaleMiddle AgedAdultRetrospective StudiesTreatment OutcomeSomatostatin

Substanzen

ThyrotropinSomatostatin

Autor:innen und Institutionen

  • Endocrinology Research Centre.

Zitieren

APA

Trukhina, D. A., Przhiyalkovskaya, E. G., Belaya, Z. E., Grigoriev, A. Y., Azizyan, V. N., Mamedova, E. O., Rozhinskaya, L. Y., Lapshina, A. M., Pigarova, E. A., Dzeranova, L. K., Platonova, N. M., Troshina, E. A., & Melnichenko, G. A. (2023). Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients. Problems of Endocrinology. https://doi.org/10.14341/probl13325

Vancouver

Trukhina DA, Przhiyalkovskaya EG, Belaya ZE, Grigoriev AY, Azizyan VN, Mamedova EO, et al. Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients. Problems of Endocrinology. 2023. doi:10.14341/probl13325

BibTeX
@article{Trukhina2023,
  author = {Trukhina, D A and Przhiyalkovskaya, E G and Belaya, Zh E and Grigoriev, A Yu and Azizyan, V N and Mamedova, E O and Rozhinskaya, L Ya and Lapshina, A M and Pigarova, E A and Dzeranova, L K and Platonova, N M and Troshina, E A and Melnichenko, G A},
  title = {Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients},
  journal = {Problems of Endocrinology},
  year = {2023},
  doi = {10.14341/probl13325}
}
Kostenlos starten →